Uniswen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-01-2025
- Paid Up Capital ₹ 0.50 M
as on 09-01-2025
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Revenue 33.98%
(FY 2020)
- Profit -14062.17%
(FY 2020)
- Ebitda -321.22%
(FY 2020)
- Net Worth -570.52%
(FY 2020)
- Total Assets -59.68%
(FY 2020)
About Uniswen Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pandit Ghorpade, Rajendra Dixit, Shailesh Phaldessai, and One other member serve as directors at the Company.
- CIN/LLPIN
U85100PN2016PTC164976
- Company No.
164976
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2016
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- LocationPune, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Uniswen Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pandit Ghorpade  | Director | 14-Jun-2016 | Current |
| Rajendra Dixit | Director | Current | |
| Shailesh Phaldessai | Director | 14-Jun-2016 | Current |
| Yashwant Bhujbal | Additional Director | Current |
Financial Performance of Uniswen Pharmaceuticals.
Uniswen Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 33.98% increase. The company also saw a substantial fall in profitability, with a 14062.17% decrease in profit. The company's net worth observed a substantial decline by a decrease of 570.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uniswen Pharmaceuticals?
Unlock access to Uniswen Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Specura Pharmaceuticals Private LimitedActive 4 years 24 daysRajendra Dixit and Yashwant Bhujbal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Uniswen Pharmaceuticals?
Unlock and access historical data on people associated with Uniswen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uniswen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uniswen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.